Insurance coverage for a GLP-1 depends on the exact product, why it was prescribed and the rules of the drug plan. Our comparison of Zepbound and Wegovy explains why the approved use and formulation can differ even when both drugs are discussed for weight management. The plan or program determines how those details affect coverage [1] [3].
How to check commercial insurance coverage
Start with your plan’s current drug list, also called a formulary, then check the coverage criteria for the exact product. HealthCare.gov advises Marketplace members to use their insurer’s website, coverage materials or member services to check what is covered [1]. If you have employer coverage, use the documents for your own plan year and benefit option.
- Give the plan the drug name, formulation and the reason your clinician prescribed it.
- Ask whether the drug needs prior authorization, a different medicine first, or a particular pharmacy.
- Ask what you would pay for a fill, whether the deductible applies and how long an approval would last.
- If the plan denies coverage, ask for the reason in writing and for its exception or appeal instructions.
A clinic membership and the medication can be separate charges. If you are comparing self-pay options, the GLP-1 price check benchmarks a monthly quote against published figures for the same medication and form. Ask your plan or pharmacy what you would owe for the prescription and check separately whether a provider charges for visits.
A care program can sit alongside your drug benefit. With FOLX Health, ask whether insurance covers the membership, visits and medication separately. If your plan offers 9amHealth or FlyteHealth, ask how enrollment works and where to check what the pharmacy will charge.
How the Medicare GLP-1 Bridge works
The Bridge is a CMS demonstration running from July 1, 2026, through December 31, 2027. Eligible people with Medicare Part D pay $50 at the pharmacy for a 28- or 30-day supply, depending on the drug. That payment does not count toward the Part D deductible or annual out-of-pocket limit [2] [3].
CMS lists Foundayo tablets, Wegovy injections and tablets, and Zepbound KwikPen for the Bridge when used for weight management. Zepbound vials and single-dose pens are outside that list. For the tablet option, our orforglipron guide explains what Foundayo is and how it differs from oral semaglutide [3].
Who may qualify for the Bridge?
The prescriber submits a separate Bridge prior authorization. CMS looks at the clinical criteria when GLP-1 therapy began, including for people who started before July 2026 or before entering Part D. The prescriber must attest to use for weight management alongside ongoing lifestyle changes and document one of these adult eligibility paths [3].
- BMI of 35 or higher at treatment initiation.
- BMI of 30 or higher with heart failure with preserved ejection fraction, uncontrolled hypertension as defined by CMS, or chronic kidney disease at stage 3a or above.
- BMI of 27 or higher with prediabetes, a previous heart attack or stroke, or symptomatic peripheral artery disease.
Check the CMS provider guidance for the exact clinical definitions. BMI alone cannot establish approval because the program also checks Part D enrollment, the prescribed use and the other requirements [3].
When to use ordinary Part D
CMS directs prescriptions for Part D-covered indications to the drug plan. Its guidance identifies type 2 diabetes, moderate to severe obstructive sleep apnea and qualifying noncirrhotic MASH as examples. For a prescription written to reduce major cardiovascular events, including one also intended for weight management, the prescriber should use the Part D plan. The Bridge does not replace that route if the plan omits a drug from its formulary or charges more[3] [4].
How to check Medicaid coverage
Check your state Medicaid program’s preferred drug list and the rules for your exact Medicaid plan. CMS’s BALANCE model is voluntary, so its product list does not establish coverage in every state. Ask the plan about the exact product, the indication and the current prior authorization requirements[5] [6].